Special Issue "Glioblastoma: Mechanics of Development, Progression and New Surgical and Clinical Management"

A special issue of Neurology International (ISSN 2035-8377).

Deadline for manuscript submissions: 31 December 2023 | Viewed by 1877

Special Issue Editor

Department of Neurosurgery, Azienda Ospedaliera Universitaria Pisana (AOUP), University of Pisa, 56010 Pisa, Italy
Interests: brain tumor; glioblastoma multiforme; low-grade glioma; meningioma; schwannoma; augmented reality; tractography; neurosurgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Glioblastoma is a diffusely infiltrative malignant brain tumor that leads to significant morbidity and mortality among affected patients. The new 2021 WHO Classification of Tumors of the Central Nervous System opened new horizons in molecular changes and in clinical and surgical practice.

Due to the extremely poor prognosis, it is imperative to investigate new and altered molecular mechanisms that may be involved in glioblastoma pathogenesis. Despite recent new studies and technologies, due to unfavorable prognosis, it is essential to look for novel, potentially change molecular processes involved in the disease's etiology and progression that may lead to the creation of more effective therapeutic strategies. Research on novel adjuvant agents, advanced personalized molecular diagnostics and response to novel targeted molecular therapies for the treatment of glioblastoma is promising.

This special issue covers all aspects of glioblastoma, including surgical innovations, original research on current and experimental treatment options, studies on molecular characteristics of glioblastoma, as well as mechanisms underlying growth inhibition: apoptosis, autophagy, necrosis.

The aim of this special issue will be to contribute to a better understanding of tumor heterogeneity/microenvironment, the different molecular signature in GBM subtypes and the relative contributions of glioma stem cells. Original papers, systematic reviews, meta-analyses and quality-of-life focused stereotactic radiosurgery, brain surgery, interstitial laser thermotherapy and oncology studies on this topic of interest are welcome.

Dr. Nicola Montemurro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Neurology International is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • glioblastoma cell line
  • target therapy
  • grosso-total resection
  • molecular markers
  • glioblastoma
  • signalling pathways
  • epigenomics
  • tumor heterogeneity
  • oncogenes
  • exosomes
  • tumor microenvironment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Macrophages in Recurrent Glioblastoma as a Prognostic Factor in the Synergistic System of the Tumor Microenvironment
Neurol. Int. 2023, 15(2), 595-608; https://doi.org/10.3390/neurolint15020037 - 23 Apr 2023
Cited by 4 | Viewed by 1618
Glioblastoma (GBM) is a common and highly malignant primary tumor of the central nervous system in adults. Ever more recent papers are focusing on understanding the role of the tumor microenvironment (TME) in affecting tumorigenesis and the subsequent prognosis. We assessed the impact [...] Read more.
Glioblastoma (GBM) is a common and highly malignant primary tumor of the central nervous system in adults. Ever more recent papers are focusing on understanding the role of the tumor microenvironment (TME) in affecting tumorigenesis and the subsequent prognosis. We assessed the impact of macrophages in the TME on the prognosis in patients with recurrent GBM. A PubMed, MEDLINE and Scopus review was conducted to identify all studies dealing with macrophages in the GBM microenvironment from January 2016 to December 2022. Glioma-associated macrophages (GAMs) act critically in enhancing tumor progression and can alter drug resistance, promoting resistance to radiotherapy and establishing an immunosuppressive environment. M1 macrophages are characterized by increased secretion of proinflammatory cytokines, such as IL-1ß, tumor necrosis factor (TNF), IL-27, matrix metalloproteinase (MMPs), CCL2, and VEGF (vascular endothelial growth factor), IGF1, that can lead to the destruction of the tissue. In contrast, M2 is supposed to participate in immunosuppression and tumor progression, which is formed after being exposed to the macrophage M-CSF, IL-10, IL-35 and the transforming growth factor-ß (TGF-β). Because there is currently no standard of care in recurrent GBM, novel identified targeted therapies based on the complex signaling and interactions between the glioma stem cells (GSCs) and the TME, especially resident microglia and bone-marrow-derived macrophages, may be helpful in improving the overall survival of these patients in the near future. Full article
Show Figures

Figure 1

Back to TopTop